A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

Summary

This study evaluates the safety and efficacy of lesinurad administered with an XOI versus a placebo plus an XOI in gout participants who have moderate renal impairment and who are not at target level of serum urate (sUA).

Timeline

Start

2017-07-19

Primary completion

2019-02-25

Completion

2019-02-25

Outcome

Outcome not reported

Stopped (Business): “This action was a business decision \& not related to any efficacy, safety or clinical concerns with lesinurad.”

Drugs

Indications